RONKONKOMA, N.Y.–()–ReCor
Medical, an emerging medical device company, reported
today six-month follow-up data on eight patients who have been treated
via renal denervation for their resistant hypertension with the
Company’s PARADISE® System—the only system for renal denervation that is
based on ultrasound, not radiofrequency, energy.
“These clinical results strongly suggest a significant competitive
advantage for ReCor’s ultrasound-based PARADISE system
compared to radiofrequency-based standard of care for
treating resistant hypertension patients”
At six months follow-up, the PARADISE data showed that
office systolic blood pressure was reduced by an
average of 33 mm Hg in 8 patients. Of note: there were also
significant and sustained blood pressure reductions in home and
ambulatory measurements at six months. The scientific literature
demonstrates that only a 5 mm Hg reduction in BP results in a 14%
decrease in stroke, a 9% decrease in heart disease, and a 7% decrease in
mortality.
“These clinical results strongly suggest a significant competitive
advantage for ReCor’s ultrasound-based PARADISE system
compared to radiofrequency-based standard of care for
treating resistant hypertension patients,” said Mano Iyer, CEO,
ReCor Medical.
The PARADISE ultrasound catheter was designed with the aim to
allow complete circumferential
denervation more consistently and efficiently than the standard of care radiofrequency
ablation catheter. The procedure with the PARADISE system only requires
30 seconds of energy delivery per treatment location, thereby
dramatically reducing the overall procedure time.
ReCor also announced that it has published a collection of video
interviews conducted during ‘EuroPCR 2012’ with key opinion
leaders (KOLs) on the topic of RENAL DENERVATION to treat resistant
hypertension. (Click link above to see these videos.)
About ReCor Medical, Inc.
Founded in 2009, ReCor is a private venture-backed, early-stage company
developing novel therapeutic ultrasound catheter technology.
ReCor is backed by European and U.S. investors including Sofinnova
Partners, one of the largest life science investors in Europe. The
Company’s PARADISE™ technology for renal denervation is CE-marked. For
more information about ReCor Medical, please visit the Company’s website
at www.recormedical.com.
NOTE: PARADISE™ is approved for sale in Europe; it is not
approved for sale or investigational use in the United States.
